Global RSV Prevention Product (for infants) Implementation Tracker Shaolong Ren¹, Bingbing Cong¹, You Li¹* — ¹Department of Epidemiology, Nanjing Medical University; *Correspondence: you.li@njmu.edu.cn

This dashboard provides a global overview of the adoption of RSV prevention products for infants. Data up to: June 2025.

Searching Method

Information on the licensing and implementation status of the long-acting monoclonal antibody Nirsevimab and the maternal RSV vaccine RSVpreF across countries was collected through systematic web searches using keywords such as “nirsevimab”, “RSVpreF”, “monoclonal antibod”, “maternal vaccine”, “RSV”, “licens”, and “approv”*, as well as local-language equivalents, each combined with country names. We also supplemented and cross-validated these data using information from the WHO internal report (up to June 2025) to generate the final list.

Search results were cross-validated using official national regulatory and health authority websites, as well as published literature.

Terminology

Licensed: Approved but not yet included in national immunisation programmes (NIPs).
NIP-included: Approved and included in NIPs.
Income level: Based on World Bank income classification (2019).
WHO region: As defined by WHO official regional groupings

Despite our efforts, omissions may exist.If you spot any missing or incorrect information, please feel free to contact us(Infectious Diseases Epi & Model Group) at slren@njmu.edu.cn — your feedback is highly appreciated!